OR WAIT null SECS
Sartorius Stedim Biotech (SSB) has agreed to acquire parts of Danaher’s Life Science portfolio.
Sartorius Stedim Biotech (SSB) has agreed to acquire parts of Danaher’s Life Science portfolio. The deal is part of a broader transaction between Danaher and Sartorius Group, SSB’s major shareholder, for $750 million. The total purchase price is approximately $750 million in cash of which about a quarter will be allocated to the businesses purchased by SSB.
The transaction is expected to be completed early 2020, however, it is subject to customary closing conditions and the successful acquisition of the GE Biopharma business by Danaher.
“The portfolio proposed for acquisition represents an excellent strategic fit with Sartorius Stedim Biotech,” said Joachim Kreuzburg, SSB Chairman of the Board and CEO. “With the chromatography hardware and resins and the microcarrier businesses we broaden our strong bioprocessing offering, particularly in the downstream area. We look very much forward to welcoming the new teams to Sartorius and to jointly combine our capabilities for the benefit of our biopharma and life science customers.”
For more information, please visit: https://www.sartorius.com/en